GlassScriptPhysician profile
Jiangyong Min
NPI 1811152887
$4,011.82
in general payments reported to CMS, 2019-2025
11 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,792 · 2022: $997 · 2023: $948 · 2024: $136 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660 · Consulting Fee: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.54 |
| Consulting Fee | $563.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,827.59 | 2021-2025 | Solitaire X, Linq II |
| Abbott Laboratories | $500.00 | 2021 | |
| Ucb, INC. | $161.30 | 2022-2024 | Briviact |
| Stryker Corporation | $137.80 | 2023 | Trevo |
| Genentech USA, INC. | $124.99 | 2021 | |
| Genentech, INC. | $102.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $89.21 | 2023 | Andexxa |
| Pfizer INC. | $21.49 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.01 | 2024 | Dysport |
| Chiesi USA, INC. | $16.53 | 2024 | Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiangyong Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.